All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Multiple companies are pursuing CD47-blockade as a tumor immunotherapy approach. Sana Biotechnology Inc., too, is interested in the therapeutic potential of CD47 – but from a very different angle. By overexpressing CD47 on stem cells, researchers at Sana want to make transplanted cells invisible to the immune system.